TXMD TherapeuticsMD Inc

Price (delayed)

$1.83

Market cap

$21.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.68

Enterprise value

$23.09M

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women ...

Highlights
TXMD's quick ratio is up by 17% year-on-year and by 8% since the previous quarter
TXMD's debt is down by 11% year-on-year and by 3.3% since the previous quarter
The net income has plunged by 105% YoY but it is up by 28% from the previous quarter
The company's EPS has shrunk by 104% YoY but it rose by 31% QoQ
The gross profit has plunged by 98% YoY and by 8% from the previous quarter
TXMD's revenue has dropped by 98% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of TXMD
Market
Shares outstanding
11.53M
Market cap
$21.1M
Enterprise value
$23.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
17.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.25
Earnings
Revenue
$1.2M
EBIT
-$7.5M
EBITDA
-$6.47M
Free cash flow
-$14.73M
Per share
EPS
-$0.68
Free cash flow per share
-$1.28
Book value per share
$2.49
Revenue per share
$0.1
TBVPS
$3.13
Balance sheet
Total assets
$42.09M
Total liabilities
$13.42M
Debt
$6.32M
Equity
$28.66M
Working capital
$5.06M
Liquidity
Debt to equity
0.22
Current ratio
1.78
Quick ratio
1.17
Net debt/EBITDA
-0.31
Margins
EBITDA margin
-539.9%
Gross margin
100%
Net margin
-617.9%
Operating margin
-583.7%
Efficiency
Return on assets
-15.6%
Return on equity
-25.3%
Return on invested capital
-25.9%
Return on capital employed
-21.1%
Return on sales
-625.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TXMD stock price

How has the TherapeuticsMD stock price performed over time
Intraday
-1.08%
1 week
7.65%
1 month
-9.85%
1 year
-53.44%
YTD
-18.67%
QTD
13.66%

Financial performance

How have TherapeuticsMD's revenue and profit performed over time
Revenue
$1.2M
Gross profit
$1.2M
Operating income
-$7M
Net income
-$7.41M
Gross margin
100%
Net margin
-617.9%
TherapeuticsMD's operating income has shrunk by 143% YoY but it has increased by 18% QoQ
The net income has plunged by 105% YoY but it is up by 28% from the previous quarter
The gross profit has plunged by 98% YoY and by 8% from the previous quarter
TXMD's revenue has dropped by 98% year-on-year and by 8% since the previous quarter

Growth

What is TherapeuticsMD's growth rate over time

Valuation

What is TherapeuticsMD stock price valuation
P/E
N/A
P/B
0.74
P/S
17.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.25
The company's EPS has shrunk by 104% YoY but it rose by 31% QoQ
The stock's price to book (P/B) is 33% less than its last 4 quarters average of 1.1
The equity has contracted by 10% YoY and by 2.1% from the previous quarter
TXMD's revenue has dropped by 98% year-on-year and by 8% since the previous quarter
TXMD's price to sales (P/S) is 73% higher than its last 4 quarters average of 10.3 and 68% higher than its 5-year quarterly average of 10.6

Efficiency

How efficient is TherapeuticsMD business performance
TXMD's return on assets has dropped by 111% year-on-year but it is up by 22% since the previous quarter
The ROIC has plunged by 100% YoY but it has increased by 33% from the previous quarter
TherapeuticsMD's ROE has increased by 26% from the previous quarter
The company's return on sales rose by 21% QoQ

Dividends

What is TXMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXMD.

Financial health

How did TherapeuticsMD financials performed over time
TXMD's total liabilities has dropped by 51% year-on-year and by 4.3% since the previous quarter
TherapeuticsMD's current ratio has increased by 39% YoY and by 3.5% from the previous quarter
TXMD's debt is 78% smaller than its equity
TXMD's debt is down by 11% year-on-year and by 3.3% since the previous quarter
The equity has contracted by 10% YoY and by 2.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.